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BACKGROUND
Respiration is the process by which vertebrates acquire oxygen
(O2) and rid themselves of carbon dioxide (CO2). Mammals do
this at the air/liquid interface in the lungs. Some vertebrates,
from lower on the evolutionary ladder (e.g. fish), do it across a
liquid/liquid interface. Thus making the concept of liquid ventil-
ation a very ancient one.
The achievement of artificial respiration by liquid ventilation in
mammals was first tried in mice in the 1960s with salt solutions
under hyperbaric conditions.1 Further experiments in the 1960s
showed the successful use of fluorocarbons at atmospheric
pressure for liquid ventilation in cats and mice.2 Initial experi-
ments with perfluorocarbons (PFC) were performed with sponta-
neously breathing animals immersed in PFC or with gravity
assisted tidal bulk flow of PFC. These techniques were unsuc-
cessful at removing enough CO2.3–5 In the 1970s and 1980s the
development of time-cycled, pressure-limited mechanical venti-
lators allowed the development of the technique of total liquid
ventilation (TLV).6 Total liquid ventilation can be used to maintain
adequate gas exchange in animals.7 It has also been shown to
improve gas exchange and lung function in animal models of
respiratory distress.8–11 In 1991, Fuhrman et al.12 introduced the
technique of using functional residual capacity (FRC) volumes of
PFC with conventional gas ventilation – PFC associated gas
exchange (PAGE). This technique has become known as partial
liquid ventilation (PLV) and it is this technique which has the
most promise for practical clinical application.
Perfluorocarbon liquids are a group of chemicals derived from
the fluorination of organic compounds such as benzene. They
are colourless, odourless liquids and are chemically and biologi-
cally inert. Perfluorocarbons are insoluble in water and almost
insoluble in lipid. They are more dense than water and soft
tissue, and they can dissolve more than 20 times the amount of
O2, and three times the amount of CO2, than water. They have a
low viscosity and surface tension, and most will evaporate faster
than water.13,14 The physical properties of some PFC liquids
used for PLV are summarized in Table 1.
PARTIAL LIQUID VENTILATION
Animal studies
Various models of lung injury and surfactant deficiency have
shown the benefits of using PLV with conventional mechanical
ventilation (CMV) compared to control animals (dogs, rabbits,
lambs and pigs). Many animal studies have shown improve-
ment in oxygenation, CO2 removal and lung compliance.15–21 It
has also been shown to be more effective than surfactant
alone in a premature lamb model of respiratory distress
syndrome.19 Studies that looked at lung histology have shown
significantly less damage in lungs after PLV.16,17 The need for
lower peak inspiratory pressures to achieve adequate tidal
volumes has been demonstrated.15 PLV has been shown to
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decrease intrapulmonary shunting.22 In all animal studies
haemodynamic stability of PLV animals has been demonstrated
to be equal to control animals.15–22 Partial liquid ventilation has
been shown to have increased improvement on oxygenation
when combined with nitric oxide in pulmonary hypertension in
piglets.22
Whilst most of these studies have demonstrated benefits of
PLV over only a few hours, two studies have demonstrated the
feasibility of longer periods of PLV. Neonatal piglets with normal
lungs ventilated for 24 h had stable ventilation and similar blood
gases compared with controls and no haemodynamic deteriora-
tion was noted in either group.23 A recent study in newborn
piglets with surfactant deficiency demonstrated improvement in
oxygenation and lung histology with up to 20 h PLV.16
The technique has also been used with high frequency venti-
lation (HFV). Animal studies investigating the effects of PLV 
with HFV have shown the technique provides good gas
exchange.16,24–27 Only two of the studies directly compared a HFV-
PLV group with a HFV alone control group.16,24 Baden et al.24
showed that the addition of PLV to HFV gave an immediate
improvement in oxygenation but this was no different to the HFV
alone group after 2 h. They used a maximal alveolar recruitment
strategy during the treatment phase with 15 s, 30 cmH2O sigh
breaths every 60 min in both groups. Sukumar et al.27 showed
improved gas exchange and pulmonary blood flow with HFV-
PLV. A mean airway pressure of 15 cmH2O was maintained
throughout without the addition of sigh breaths. Smith et al.,26
comparing various methods of HFV-PLV, showed that those
forms of HFV which allow volume recruiting manoeuvres, such
as the addition of intermittent conventional breaths, gave
superior gas exchange. It seems that, with the use of strategies
aimed at maximal alveolar recruitment, HFV-PLV may not confer
any additional benefit over HFV alone.
Most of the PFC instilled into the lungs evaporates into the
expired air.14 Since PFC is insoluble in water, all the PFC in
blood or tissue is dissolved in lipid. Small amounts of PFC are
detected in the blood of liquid-ventilated animals.28 Uptake of
PFC by other tissues is dependent on its blood flow and fat
content, with highest levels (apart from the lungs) found in fat,
brain and intestine.28 Probably minuscule amounts are trans-
pired through the skin. There is also an uptake of PFC by
macrophages in the lung, liver and spleen.14 Perfluorocarbon
has been detected in the tissues of beagle dogs 3 years after
1 hour of total liquid ventilation.29
Human studies
There have been several published reports of the use of PLV in
human neonates.30–36 All these studies have been uncontrolled.
The most significant study reported by Leach et al.,34 who
reported the use of PLV in 13 premature infants (gestational age
mean 28, range 24–33 weeks) with severe respiratory distress
syndrome – all were failing conventional therapy. Ten infants had
24–72 h of PLV and had demonstrated improvement in oxygen-
ation and lung compliance. Six out of 10 survived to 36 weeks
corrected age. The PLV was said to be well tolerated without any
haemodynamic disturbance.
Pranikoff et al.32 reported the use of PLV in newborn infants
with congenital diaphragmatic hernia. Partial liquid ventilation
was used in four infants, all of whom were on extracorporeal life
support at the time. The authors noted improvement in oxygen-
ation and total lung compliance with haemodynamic stability and
no respiratory deterioration or other acute adverse effects.
Fuhrman et al.37 have reported results from a prematurely
halted clinical trial in paediatric acute respiratory distress
syndrome (ARDS). The trial protocol underwent a number of
amendments during the trial, resulting in three different sets 
of inclusion criteria. The final group, with liberalized entry
criteria, had an unexpected decrease in mortality in the control
group and the trial was stopped to allow full data analysis to
determine the safety of PLV in this patient group. One hundred
and eighty-two patients were enrolled (< 20% of target enrol-
ment) with overall mortality of 24/91 (26%) in the PLV group and
18/91 (20%) in the conventional mechanical ventilation group.
The authors concluded that PLV with LiquiVent® (Alliance
Pharmaceutical Corp., San Diego, CA, USA) was safe; however,
it was underpowered to detect real differences in mortality and
ventilator free days between the groups.
Partial liquid ventilation technique
Perfluorocarbon is instilled into the endotracheal tube (ETT),
usually through the side-port of the ETT manifold, whilst gas venti-
lation (CMV or HFV) continues. The initial volume of PFC used will
be equal to the patient’s estimated FRC. This volume of PFC is
given over 10–20 min until a fluid level is seen in the ETT when the
ventilator is disconnected (that is when positive end expiratory
pressure (PEEP) = 0). Repeated doses of PFC are given at regular
intervals to maintain a fluid level in the ETT at a PEEP of zero.
Repeated doses of PFC are needed because the FRC will
increase as the liquid recruits more collapsed alveoli and to replace
evaporative losses. Cessation of PLV is merely achieved by ceas-
ing top ups of PFC. The process is identical when used with HFV.
Nursing care of the patient on PLV will generally be similar to
that for any ventilated critically ill patient.38 Optimum techniques
for instillation of PFC may require multiple re-positioning of the
patient in the early stages of initiating PLV. Regular or continuous
topping up of PFC down the ETT (especially to replace any PFC
removed with suction) will be required. Lavaged exudate, which is
less dense than PFC, will float to the top of the air/liquid interface
and may block large airways and the ETT – therefore close
attention to airway management and suctioning will be required.
How partial liquid ventilation works
The characteristics of PFC determine the effects of PLV. During
gas ventilation nitrogen is the inert carrier of O2 and CO2. In
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Table 1 Physical properties of some perfluorocarbons compared with
saline
Saline FC-77 Rimar Perflubron APF-140
Density 1.0 1.78 1.78 1.93 1.95
(g/mL)*
Kinematic viscosity 1.0 0.8 0.82 1.10 2.90
(centistokes)*
Vapour pressure 47 85 63 11 14
(mmHg)†
Surface tension 72 15 15 18 15
(dynes/cm)*
O2 solubility 3.0 50 52 53 49
(ml/100 mL)*
CO2 solubility 57 198 160 210 140
(ml/100 mL)†
* 25°C; †37°C.
liquid ventilation, nitrogen is replaced by PFC. It has a high
oxygen carrying capacity and solubility for CO2,13,36 and the 
PFC is oxygenated and CO2 removed by means of tidal gas
movement provided by the gas ventilator. This appears to be true
in either conventional or high frequency ventilation. The low
viscosity facilitates movement of PFC in small peripheral airways.
PFC have a low surface tension.13 When it is instilled into the
lung, the air/liquid alveolar interface (which in the surfactant
deficient lung has a high surface tension) is abolished thereby
lowering surface tension, increasing compliance and increasing
alveolar recruitment. This allows lower ventilator pressures to 
be used and thus decreasing baro-and volu-trauma. Perfluoro-
carbons do not disturb natural surfactant39 production nor do
they wash it out of the lungs.40,41
Perflurocarbons have a high density compared to water and
soft tissue,13 and will mechanically recruit collapsed alveoli. This
will happen preferentially in the dependant portions of the lung
therefore improving ventilation/perfusion matching and decreasing
intrapulmonary shunting.42 Less dense exudate and debris may
be lavaged from peripheral airways and float to the top of the PFC
to allow removal by suction.17,42
Other uses of perfluorocarbons in the lung
Drug delivery to the pulmonary circulation has been demon-
strated with TLV in neonatal lambs (with acetylcholine, adrena-
line and priscoline).43 The potential for delivery of drugs to the
pulmonary vasculature with PLV enhances the prospect of
treating patients with pulmonary hypertension. This has already
been demonstrated in animal models using PLV with nitric
oxide,22 but the use of other pulmonary vasodilators may be
possible. Partial liquid ventilation may also be used to deliver
bronchodilators, exogenous surfactant, antibiotics, antioxidants,
steroids and chemotherapeutic agents.
Lung washout with PFC can not only remove exudate and
debris (such as meconium) from the lungs but may also play a
role in washing out inflammatory mediators which have been
implicated in secondary lung damage.42 Warming or cooling of
PFC used for PLV can facilitate temperature manipulation and
control.38 Perflurocarbons are radiopaque and have minimal
physiologic effects when instilled into the lungs and therefore
have the potential for use as a X-ray contrast medium.33,34,37
Because PFC can eliminate the air/liquid interface in the lung, it
may facilitate ultrasound examination of the lungs.
THE FUTURE
Perflubron (LiquiVent®) is the only medical grade PFC
licensed for use in America. It is the PFC used in almost all the
clinical trials of PLV to date. Randomized controlled trials
(RCT) will obviously be needed for the use of perflubron in
various respiratory problems in infants and children. Whilst
further phase three clinical trials are currently being planned,
ongoing fine tuning of the techniques of PLVin the animal lab
are necessary so that RCT are performed properly before
widespread use of the technique in intensive care. We should
acknowledge the lesson of the HIFI trial45 and its misleading
results.45
Many questions about PLV remain unanswered. What is the
ideal dose of PFC? Is continuous PLV required or will inter-
mittent bolus doses of PFC (acute alveolar recruitment) provide
sufficient benefit? Does the instillation of PFC into the lungs
have any effect on the cerebral circulation (especially in the
immature brain)? What are the long-term effects of perflubron
after the cessation of PLV? Does the PFC need to be
oxygenated prior to use?
Liquid ventilation, especially PLV, promises to be an exciting
new therapy for infants and children with a variety of respiratory
problems. The biggest challenge will be to conduct clinical trials
comparing conventional techniques with the best possible
method of PLV. Determining the best possible method of using
PLV requires ongoing research and experimentation.
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